H-FABP in combination with GFAP and the age of the patient has been found to be the best combination to rule out the mild Traumatic Brain Injury (mTBI) patients improving specificity above 50%

TBICheckTM, the first point-of-care portable device to detect TBI with a simple drop of bloodis now CE marked and will be soon commercially available

Geneva, March 18th, 2019. Researchers from the University of Geneva (Switzerland) and the Vall d’Hebron Institute of Research (VIHR) from Barcelona (Spain) have presented at the 13th IBIA Congress, results on biomarkers and panels of biomarkers to better manage mTBI patients and their future outcomes.

H-FABP in combination with GFAP and the age of the patient has been found to be the best combination to rule out the mild Traumatic Brain Injury (mTBI) patients improving specificity above 50%

TBICheckTM, the first point-of-care portable device to detect TBI with a simple drop of bloodis now CE marked and will be soon commercially availableGeneva, March 18th, 2019. Researchers from the University of Geneva (Switzerland) and the Vall d’Hebron Institute of Research (VIHR) from Barcelona (Spain) have presented at the 13th IBIA Congress, results on biomarkers and panels of biomarkers to better manage mTBI patients and their future outcomes.